ReviewCancer metastasis reviews2025
Effects of aging on anticancer therapy in murine cancer models.
Review in Cancer metastasis reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
More than half of cancer patients are over 65 years old. This proportion will increase with further population aging. Cancer properties significantly depend on patients' age, and, as a rule, cancer responsiveness to therapy decreases with patients' aging. However, aged patients are underrepresented in clinical trials, and the preclinical trials of anticancer therapy are almost invariably carried out using young mice. Compared to innumerable studies of the effects of age on carcinogenesis in mice, reports on direct comparisons of the effects of anticancer therapy in young and old mice are scarce. In the present scoping review, virtually all publications on this topic are compiled. In most cases, tumor growth inhibition and host survival improvement resulting from therapy are compromised in old mice. When adjuvant means are used to improve responses to therapy in old mice, the beneficial effects, if any, decrease with decreasing age, and thus, they may be missed in preclinical studies using young mice. Prospects for developing murine cancer models suitable for checking the effects of anticancer therapies in old patients are discussed.
Indexed as
Identifiers
40879825What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.